Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet, 2020 | 1830 | 2020 |
Current trends and emerging future of indocyanine green usage in surgery and oncology: a literature review K Polom, D Murawa, Y Rho, P Nowaczyk, M Hünerbein, P Murawa Cancer 117 (21), 4812-4822, 2011 | 279 | 2011 |
Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 170 | 2021 |
Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine green–human serum albumin in comparison with gamma emitting radioactive … K Polom, D Murawa, P Nowaczyk, YS Rho, P Murawa European Journal of Surgical Oncology (EJSO) 38 (2), 137-142, 2012 | 78 | 2012 |
Comparing clinical characteristics and outcomes of young-onset and late-onset colorectal cancer: an international collaborative study YS Rho, M Gilabert, K Polom, A Aladashvili, K Kopeckova, V Megdanova, ... Clinical colorectal cancer 16 (4), 334-342, 2017 | 57 | 2017 |
Usage of invisible near infrared light (NIR) fluorescence with indocyanine green (ICG) and methylene blue (MB) in urological oncology. Part 1 W Polom, M Markuszewski, YS Rho, M Matuszewski Central European journal of urology 67 (2), 142, 2014 | 48 | 2014 |
Racial disparities in COVID-19 outcomes among black and white patients with cancer J Fu, SA Reid, B French, C Hennessy, C Hwang, NT Gatson, N Duma, ... JAMA network open 5 (3), e224304-e224304, 2022 | 47 | 2022 |
Adjuvant therapy for stages II and III colon cancer: Risk stratification, treatment duration, and future directions U Bender, YS Rho, I Barrera, S Aghajanyan, J Acoba, P Kavan Current Oncology 26 (s1), 43-52, 2019 | 41 | 2019 |
Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ... JAMA network open 4 (11), e2134330-e2134330, 2021 | 40 | 2021 |
Use of invisible near infrared light fluorescence with indocyanine green and methylene blue in urology. Part 2 W Polom, M Markuszewski, YS Rho, M Matuszewski Central European journal of urology 67 (3), 310, 2014 | 33 | 2014 |
Skin melanoma sentinel lymph node biopsy using real‐time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin K Polom, D Murawa, YS Rho, A Spychala, P Murawa British Journal of Dermatology 166 (3), 682-683, 2012 | 33 | 2012 |
Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19 Z Bakouny, C Labaki, P Grover, J Awosika, S Gulati, CY Hsu, ... JAMA oncology 9 (1), 128-134, 2023 | 31 | 2023 |
Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer J McLean, YS Rho, G Kuruba, A Mamo, M Gilabert, T Kavan, L Panasci, ... Clinical colorectal cancer 15 (2), 135-140, 2016 | 31 | 2016 |
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma M Gilabert, B Chanez, YS Rho, M Giovanini, O Turrini, G Batist, P Kavan, ... Medicine 96 (16), e6544, 2017 | 25 | 2017 |
Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization TY Wang, AS Wahed, A Morris, LB Kreuziger, JG Quigley, GA Lamas, ... Annals of internal medicine 176 (4), 515-523, 2023 | 20 | 2023 |
Quantifying treatment delays in adolescents and young adults with cancer at McGill University Y Xu, M Stavrides-Eid, A Baig, M Cardoso, YS Rho, WM Shams, A Mamo, ... Current Oncology 22 (6), 470-477, 2015 | 20 | 2015 |
A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance M Abidi, DM Aboulafia, MK Accordino, JD Acoba, MS Ahluwalia, ... Cancer cell 38 (6), 761-766, 2020 | 18 | 2020 |
Patterns and predictors of emergency department visits among older patients after breast cancer surgery: a population-based cohort study T Westley, A Syrowatka, D Henault, YS Rho, F Khazoom, SL Chang, ... Journal of geriatric oncology 9 (3), 204-213, 2018 | 15 | 2018 |
Targeted therapies provide treatment options for poorly differentiated pancreatic neuroendocrine carcinomas M Gilabert, YS Rho, P Kavan Oncology 92 (3), 170-172, 2017 | 14 | 2017 |
Progression pattern and adverse events with bevacizumab in glioblastoma A Mamo, A Baig, M Azam, YS Rho, S Sahebjam, T Muanza, S Owen, ... Current Oncology 23 (5), 468-471, 2016 | 12 | 2016 |